Aeterna Zentaris Inc. (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) was the target of a large decrease in short interest in February. As of February 29th, there was short interest totalling 20,000 shares, a decrease of 13.8% from the February 14th total of 23,200 shares. Based on an average trading volume of 13,900 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.4% of the company’s shares are short sold.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on shares of Aeterna Zentaris in a research report on Wednesday. They issued a “sell” rating for the company.
View Our Latest Research Report on Aeterna Zentaris
Aeterna Zentaris Stock Up 7.0 %
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
Featured Articles
- Five stocks we like better than Aeterna Zentaris
- Trading Stocks: RSI and Why it’s Useful
- Why Dollar General and Dollar Tree Are Similar Yet Different
- Why Are Stock Sectors Important to Successful Investing?
- Jabil Stock Implodes: Market Manufactures Entry for New Money
- 3 Monster Growth Stocks to Buy Now
- Flutter Receives Major Upgrades: Investor Interest Skyrockets
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.